Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease. Your doctor might suggest taking ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there almost a year after Eisai and Biogen's anti-amyloid rival Leqembi ...

Meanwhile, it could also help offset concerns that the rate of ARIA-E and ARIA-H are a little higher with Kisunla than with Leqembi. The company said it plans to submit the TRAILBLAZER-ALZ 6 data ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...